BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10607740)

  • 1. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.
    LaRue H; Allard P; Simoneau M; Normand C; Pfister C; Moore L; Meyer F; Têtu B; Fradet Y
    Carcinogenesis; 2000 Jan; 21(1):101-6. PubMed ID: 10607740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of cigarette smoking on P53 gene mutations in bladder carcinomas.
    Bernardini S; Adessi GL; Chezy E; Billerey C; Carbillet JP; Bittard H
    Anticancer Res; 2001; 21(4B):3001-4. PubMed ID: 11712801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
    Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
    J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 and MDM2 in the development and progression of bladder cancer.
    Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
    Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
    Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
    Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [p53 tumor suppressor gene mutation and prognosis in 105 cases of bladder cancer--the relationship between mutation of the p53 gene with clinicopathological features and smoking].
    Harano H; Wang C; Gao J; Uchida T
    Nihon Hinyokika Gakkai Zasshi; 1999 Apr; 90(4):487-95. PubMed ID: 10355250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and altered expression of p53 genes in experimental rat bladder tumor cells.
    Jones RF; Matuszyk J; Debiec-Rychter M; Wang CY
    Mol Carcinog; 1994 Feb; 9(2):95-104. PubMed ID: 8142014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
    Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
    Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutations and prognosis in bladder tumors.
    Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
    J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
    Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
    Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.
    Spruck CH; Rideout WM; Olumi AF; Ohneseit PF; Yang AS; Tsai YC; Nichols PW; Horn T; Hermann GG; Steven K
    Cancer Res; 1993 Mar; 53(5):1162-6. PubMed ID: 8439962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions.
    Ahomadegbe JC; Barrois M; Fogel S; Le Bihan ML; Douc-Rasy S; Duvillard P; Armand JP; Riou G
    Oncogene; 1995 Mar; 10(6):1217-27. PubMed ID: 7700647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.